Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06313086
Status:
RECRUITING
Last Update Posted:
2024-05-10
First Post:
2024-03-01
Brief Title:
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Organization:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Organization Data
Organization:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Class:
INDUSTRY
Study ID:
SYSA1501-009
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None